Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the financial results for the quarter and half year ended Jun 30, 2025.
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.2 pts more than Nifty Microcap 250 and 13.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi Consumer Healthcare India reported a strong Q2 FY26 (quarter ended June 30, 2025), with revenue from operations rising about 28% year-on-year to ₹2,209 million from ₹1,723 million. Profit after tax more than doubled to ₹607 million from ₹290 million in the same quarter last year, though this includes an exceptional gain of ₹66 million from reversing excess demerger-related provisions made in the previous year. For the half year, revenue was nearly flat at ₹3,935 million versus ₹3,939 million, while profit after tax rose roughly 21% to ₹1,107 million. The company is essentially debt-free with ₹2,164 million in cash and total equity of ₹2,570 million, though it paid out ₹1,267 million in dividends during the half year. Recovery from voluntary product recalls continues, with Combiflam Suspension relaunched this quarter, while Allegra Suspension and Depura Kids remain off the market. The ultimate parent changed to Opal JVco S.a.r.l after Sanofi sold a 50% controlling stake in its Opella consumer health business.
The sharp headline profit growth is largely flattered by the exceptional one-time gain and a low base, so underlying earnings momentum is more moderate. Still, strong revenue growth, a debt-free balance sheet, and ongoing product relaunches point to a healthy business in recovery mode for shareholders.